Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -33055.56% is 140% below its 5-year average of -13794.09%, around the middle of its 5-year range (-102400.00%–-60.23%).
11.08% below its 12-month average of -29758.79%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2015 (2015-09-30): -92566.67%.
EBITDA MARGIN
-33055.56%
EBITDA MARGIN AVG TTM
-29758.79%
EBITDA MARGIN AVG 3Y
-13721.25%
EBITDA MARGIN AVG 5Y
-13794.09%
EBITDA MARGIN AVG 10Y
-1965.32%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-11.08%
CURRENT VS 3Y AVG
-140.91%
CURRENT VS 5Y AVG
-139.64%
CURRENT VS 10Y AVG
-1581.94%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GT Biopharma, Inc.
Market Cap
$7.95M
EBITDA Margin
-33055.56%
TTM Avg
-29758.79%
3Y Avg
-13721.25%
5Y Avg
-13794.09%
Market Cap
$7.97M
EBITDA Margin
-194787.38%
TTM Avg
-191929.49%
3Y Avg
-133856.30%
5Y Avg
-96317.48%
Market Cap
$8.00M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$8.15M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$8.30M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
Market Cap
$7.43M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$8.53M
EBITDA Margin
-65.39%
TTM Avg
-49.20%
3Y Avg
-36.51%
5Y Avg
-25.14%
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | $7.95M | -33055.56% | -29758.79% | -13721.25% | -13794.09% |
| HeartSciences Inc. (HSCS)vs › | $7.97M | -194787.38% | -191929.49% | -133856.30% | -96317.48% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $8.00M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.15M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.30M | -334.15% | -180.95% | -121.99% | -121.99% |
| Longeveron Inc. (LGVN)vs › | $7.43M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.53M | -65.39% | -49.20% | -36.51% | -25.14% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.29% | -74.83% | -125.41% | -344.12% |
| KALA BIO, Inc. (KALA)vs › | $7.28M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
Gross Margin
0.0%
EBITDA Margin
-33055.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2015-09-30 | -92566.67% |
| 2015-06-30 | -7155.00% |
| 2015-03-31 | -25857.14% |
| 2014-12-31 | -4915.15% |
| 2014-09-30 | -18300.00% |
| 2014-06-30 | -412.00% |
| 2013-09-30 | -75.96% |
| 2013-06-30 | -130.36% |
| 2013-03-31 | -60.23% |
| 2012-12-31 | -337.10% |
| 2012-09-30 | -1124.17% |
| 2012-06-30 | -102400.00% |
| 2012-03-31 | -39400.00% |
| 2011-12-31 | -34833.33% |
| 2011-09-30 | -26750.00% |
| 2011-06-30 | -47400.00% |
| 2011-03-31 | -9255.00% |
| 2010-12-31 | -4700.00% |
| 2009-12-31 | -5384.62% |
| 2009-06-30 | -577.14% |
| 2008-12-31 | 27.38% |
| 2008-09-30 | -121.27% |
| 2008-06-30 | 20.19% |
| 2008-03-31 | -30.43% |
| 2007-12-31 | -46.75% |
| 2007-09-30 | -0.46% |
| 2007-06-30 | 35.47% |
| 2007-03-31 | -17.25% |
| 2006-12-31 | -77.42% |
| 2006-09-30 | -21.10% |
| 2006-06-30 | -32.45% |
| 2006-03-31 | -35.03% |
| 2005-12-31 | -277.66% |
| 2005-09-30 | -60.15% |
| 2005-06-30 | -57.12% |
| 2005-03-31 | -37.24% |
| 2004-12-31 | -48.54% |
| 2004-09-30 | 35.53% |
| 2004-06-30 | -133.49% |
| 2004-03-31 | -45.50% |
| 2003-12-31 | -17.32% |
| 2003-09-30 | -16.25% |
| 2003-06-30 | -34.49% |
| 2003-03-31 | -19.85% |
| 2002-12-31 | -4.84% |
| 2002-09-30 | -52.11% |
